Targeting Apelinergic System in Cardiometabolic Disease

Title:Targeting Apelinergic System in Cardiometabolic Disease

Volume: 18 Issue: 15

Author(s): Rui Guo, Olivia Rogers and Sreejayan Nair*

Affiliation:

• School of Pharmacy, University of Wyoming and the Center for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, WY 82071,United States

Keywords: Apelin, apelinergic receptor, energy metabolism, cardiovascular disease, diabetes, metabolic syndrome, polymorphism.

Abstract: Background: Global burden of cardiometabolic disease warrants development of newer treatment strategies. Apelin is ubiquitously expressed endogenous peptide which is a ligand for the apelinergic (APJ) receptor. Apelin/APJ receptors regulate a variety of biological functions and have been implicated in cardiovascular and metabolic homeostasis. Consequently, the apelinergic pathway represents an attractive target to treat conditions associated with cardiometabolic syndrome.

Objective: This review highlights the important regulatory role played by apelin in energy metabolism and cardiovascular function, and potential avenues that could be harnessed for therapeutic benefit.

Conclusion: Apelin/APJ system is a druggable target to treat or prevent a variety of cardiometabolic diseases.

Cite this article as:

Guo Rui, Rogers Olivia and Nair Sreejayan*, Targeting Apelinergic System in Cardiometabolic Disease, Current Drug Targets 2017; 18 (15) . https://dx.doi.org/10.2174/1389450117666160613105152